company background image
SYRS

Syros Pharmaceuticals NasdaqGS:SYRS Stock Report

Last Price

US$4.14

Market Cap

US$83.7m

7D

1.5%

1Y

-89.6%

Updated

27 Nov, 2022

Data

Company Financials +
SYRS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SYRS Stock Overview

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.

Syros Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Syros Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.14
52 Week HighUS$43.30
52 Week LowUS$3.52
Beta1.48
1 Month Change-10.78%
3 Month Change-49.51%
1 Year Change-89.57%
3 Year Change-91.88%
5 Year Change-97.31%
Change since IPO-97.72%

Recent News & Updates

Recent updates

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08
Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 02
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

May 11
Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

May 07
Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

Mar 02
Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Jan 26
What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Why Syros Pharmaceuticals' (NASDAQ:SYRS) CEO Pay Matters

Dec 08
Why Syros Pharmaceuticals' (NASDAQ:SYRS) CEO Pay Matters

Shareholder Returns

SYRSUS BiotechsUS Market
7D1.5%0.4%1.3%
1Y-89.6%-14.4%-18.5%

Return vs Industry: SYRS underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: SYRS underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is SYRS's price volatile compared to industry and market?
SYRS volatility
SYRS Average Weekly Movement13.5%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: SYRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: SYRS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011124Nancy Simonianhttps://www.syros.com

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd.

Syros Pharmaceuticals, Inc. Fundamentals Summary

How do Syros Pharmaceuticals's earnings and revenue compare to its market cap?
SYRS fundamental statistics
Market CapUS$83.74m
Earnings (TTM)-US$113.69m
Revenue (TTM)US$23.44m

3.6x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SYRS income statement (TTM)
RevenueUS$23.44m
Cost of RevenueUS$0
Gross ProfitUS$23.44m
Other ExpensesUS$137.13m
Earnings-US$113.69m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.62
Gross Margin100.00%
Net Profit Margin-485.12%
Debt/Equity Ratio31.4%

How did SYRS perform over the long term?

See historical performance and comparison